Nasdaq GlobeNewswire

myToys Delivers Oracle e-Business Suite Projects Faster Using Delphix Dynamic Data Platform

Del

Top European family shopping retailer selects Delphix to reduce time-to-market, improve software quality, offer faster disaster recovery, accelerate financial close and reduce costs

FRANKFURT, Germany and REDWOOD CITY, Calif., Oct.  25, 2017  (GLOBE NEWSWIRE) -- Delphix, the company that has changed the dynamics of managing and consuming data, today announced top online retailer myToys has selected the Delphix Dynamic Data Platform to support their Oracle E-Business Suite (EBS) projects and drive continuous innovation.

myToys uses Oracle EBS to run everything from purchasing, finance and accounting to order/ inventory management, customer service and logistics. By adopting the Delphix Dynamic Data Platform, myToys expects to use secure, up-to-date data to improve application development and testing processes, reduce time-to-market and improve quality.

myToys ERP embraces DevOps in many aspects of the Software Development Life Cycle, the goal of which is to strive for daily application releases that keep up with market changes; however, they found that their test automation processes were broken and inhibited both quality and speed. Before the Delphix implementation, their development team shared two environments between them to support the 70+ projects they worked on per quarter, which inhibited the development process and stifled innovation.

"With Delphix, our vision is to let any developer generate an environment on-demand risk-free with the right data and application stack. Data operators will be able to provide self-service access to developers, accelerating the speed at which they can work on critical projects," stated Ralf Schmilewski, head of ERP Development with myToys.

After evaluating potential solutions, myToys selected Delphix, as the team found the platform to be a proven solution for Oracle EBS projects. Other important factors in the decision were the mature DevOps features in the Delphix Dynamic Data Platform and ease of implementation resulting in rapid time-to-value.

Schmilewski continued, "Delphix has many Oracle EBS customers around the world and demonstrated a wealth of expertise and knowledge in their German team. We felt confident in the best practices and data expertise by the Delphix technical staff. In addition, Delphix self-service features are built for test automation. Delphix is the missing link in DevOps."

With data forecasted to grow at 20% per year, myToys is also expecting a considerable storage savings due to the way Delphix virtualizes at the data level.

"We are delighted that myToys has chosen Delphix and recognizes the value the Delphix Dynamic Data Platform will deliver to their Oracle EBS projects," explained Minas Botzoglou, Regional Sales Manager for DACH at Delphix. "We look forward to helping more companies in Europe and across the world maximize the effectiveness of DevOps investments to drive innovation."

For more information on the Delphix Dynamic Data Platform, please visit:

·        Platform Solution Brief
·        Link to the Cloud Release

About Delphix

Delphix's mission is to free companies from data friction and accelerate innovation. Fortune 100 companies use the Delphix Dynamic Data Platform to connect, virtualize, secure and manage data in the cloud and in on-premise environments. For more information visit www.delphix.com

About the MYTOYS GROUP

The MYTOYS GROUP - with headquarters in Berlin and part of the Otto Group - is one of Germany's most successful E-Commerce companies for the target group of families and women. Since 1999, the MYTOYS GROUP operates under the brand myToys Germany's leading online shop and retailer for toy, leisure product and baby care and 16 retail stores trading under the same name. myToys is the leading Multi-Channel-Provider for children's products in German speaking countries. In 2010, the women's fashion online store ambellis was launched, which also belongs to the MYTOYS GROUP. Since 2013, the online shoe shop mirapodo and the shopping community limango also belong to the MYTOYS GROUP family. With the innovative combined shopping concept, customers are able to purchase simultaneously in the online shops myToys, ambellis and mirapodo. With just one account and a shared shopping cart, the online shopping experience is easy and convenient. The MYTOYS GROUP currently employs more than 2,000 employees. Sales revenue amounted to over 500 million euros in the fiscal year 2015/16.

CONTACT:

Alex Plant / alex.plant@delphix.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Delphix via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

TESARO Announces European Commission Approval of ZEJULA® for Women With Recurrent Ovarian Cancer20.11.2017 13:00Pressemelding

ZEJULA is the first PARP inhibitor approved in Europe for women with recurrent ovarian cancer, regardless of BRCA mutation or biomarker status Approval supported by robust data from a randomized, well-controlled Phase 3 trial Only PARPi to offer once-daily, oral dosing to enable convenient administration for maintenance treatment First commercial launches planned for Germany and the UK this December ZUG, Switzerland, Nov. 20, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology focused biopharmaceutical company, announced today that the European Commission (EC) has granted marketing authorization for ZEJULA® (niraparib) as a monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete response (CR) or partial response (PR) to platinum-based chemotherapy. ZEJULA is the first once-daily, oral poly (

PledPharma and Solasia enter license agreement to develop and commercialize PledOx® in Asia20.11.2017 07:30Pressemelding

Stockholm, 2017-11-20 07:30 CET (GLOBE NEWSWIRE) -- Stockholm, Sweden / Tokyo, Japan, November 20th 2017 - PledPharma AB (“PledPharma”) (STO: PLED) and Solasia Pharma K.K. (“Solasia”) (TSE: 4597) today jointly announce that they have entered a license agreement pertaining to the clinical development and commercialization of PledOx® in Japan, China, Hong Kong, Macau, South Korea and Taiwan. Under the terms of this agreement, PledPharma grants exclusive development and commercialization rights to PledOx® in the territories mentioned and Solasia will pay upfront, development, regulatory and sales milestones of up to ~USD 83 million (SEK 700 million)*. In addition, Solasia will pay industry standard royalty rates on sales applicable for a deal pertaining to an in-licensed asset in Phase III development. Solasia will also fully finance an expansion of the Phase III program to include Asian patients subject to regulatory consultations. The license agreement is initially focused on th

CrownBio Launches an Innovative Grant Program to Fund Advancements in Preclinical Oncology Research17.11.2017 18:07Pressemelding

SANTA CLARA, Calif., Nov. 17, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces the launch of a grant program supporting oncology research scientists which provides funding for projects that show promise for scientific advancement of Patient Derived Xenograft (PDX) technology. Research Grants up to $50,000 will be awarded to projects focused on accelerating the pace of preclinical innovation and novel PDX methodologies that improve clinical predictions with sound science. The program offers an opportunity for investigators to receive funding for projects that may not receive support through traditional funding channels. Submitted proposals will be reviewed and selected by CrownBio's Scientific Steering Committee with the goa

Barings Backs Sentinel Capital Partners in Acquisition of Nekoosa17.11.2017 17:00Pressemelding

CHARLOTTE, N.C., Nov. 17, 2017 (GLOBE NEWSWIRE) -- Barings, one of the world's leading asset management firms, announced today that it served as Lead Agent on a senior secured credit facility to support Sentinel Capital Partners in its acquisition of Nekoosa ("Nekoosa" or the "Company"). Headquartered in Nekoosa, Wisconsin, the Company is a leading manufacturer of specialty paper and film products used in the graphics and commercial print markets, including application and pressure-sensitive tapes, specialty synthetic papers, sheeted digital and offset grade carbonless paper, and extruded film products. Nekoosa serves a highly diverse base of more than 70,000 commercial print and graphics shops in 65 countries. Barings served as lead senior lender on the transaction, which included a senior term loan and a revolving credit facility. "Sentinel is pleased to have Barings' support on our investment in Nekoosa," said Scott Perry, a partner with Sentinel Capital Partner

At SC17, ExaScaler and PEZY Computing Unveil Gyoukou Supercomputer with a High Combined Green500/Top500 Ranking16.11.2017 23:29Pressemelding

ExaScaler and PEZY Computing Also Take Top Three Green500 Positions DENVER, Nov. 16, 2017 (GLOBE NEWSWIRE) -- At SC17, ExaScaler and PEZY Computing unveiled their Gyoukou supercomputer whose Green500 and Top500 rankings attest to a unique combination of high efficiency and computing power. The Gyoukou supercomputer is installed at the Yokohama Research Institute in Japan. (Video: PEZY Liquid immersion cooling) PEZY supercomputers leverage 48V Factorized Power, a high efficiency, high density power distribution architecture. PEZY's CPUs are co-packaged with Vicor's Power-on-Package ("PoP") Modular Current Multipliers ("MCMs"), which enable efficient, direct 48V to sub-1V current multiplication at the XPU. ExaScaler and PEZY Computing also achieved the #1, #2 and #3 positions on the Green500. These supercomputer system installations also utilize 48V Factorized Power. Come see us at SC17 at Booth 633 where ExaScaler / PEZY Computing will be

ELS Educational Services, Inc. Launches New Vacation English Program Starting January 201816.11.2017 20:59Pressemelding

New York, New York, Nov. 16, 2017 (GLOBE NEWSWIRE) -- ELS Educational Services, Inc. - one of the leading language services providers worldwide - has launched a new vacation English language program, ELS Language Experience+, which is set to begin enrollment for January 2018. "Here at ELS, our students and their English language goals always come first, and we are proud to introduce ELS Language Experience+ as an exciting new addition to the many quality programs we offer them," said ELS Chief Operating Officer, Reiji Terasaka. "This conversation-oriented, flexible new vacation English program allows students to make the most of their English instruction while gaining an invaluable cultural experience at the same time." ELS Language Experience+ concentrates on everyday speaking, communication skills and discussion, within a flexible course structure (three or six hours of study per day). Courses offered include: Everyday English, Grammar in Action, D

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom